DE69631544D1 - Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse - Google Patents

Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse

Info

Publication number
DE69631544D1
DE69631544D1 DE69631544T DE69631544T DE69631544D1 DE 69631544 D1 DE69631544 D1 DE 69631544D1 DE 69631544 T DE69631544 T DE 69631544T DE 69631544 T DE69631544 T DE 69631544T DE 69631544 D1 DE69631544 D1 DE 69631544D1
Authority
DE
Germany
Prior art keywords
body mass
lean body
increase lean
obesity protein
increasing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69631544T
Other languages
English (en)
Other versions
DE69631544T2 (de
Inventor
Ann Pelleymounter
Francis Toombs
Michael Benjamin Mann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of DE69631544D1 publication Critical patent/DE69631544D1/de
Application granted granted Critical
Publication of DE69631544T2 publication Critical patent/DE69631544T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
DE69631544T 1995-11-22 1996-11-04 Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse Expired - Lifetime DE69631544T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56173295A 1995-11-22 1995-11-22
US561732 1995-11-22
PCT/US1996/017718 WO1997018833A1 (en) 1995-11-22 1996-11-04 Methods of increasing lean tissue mass using ob protein compositions

Publications (2)

Publication Number Publication Date
DE69631544D1 true DE69631544D1 (de) 2004-03-18
DE69631544T2 DE69631544T2 (de) 2004-12-23

Family

ID=24243198

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69631544T Expired - Lifetime DE69631544T2 (de) 1995-11-22 1996-11-04 Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse
DE69638119T Expired - Lifetime DE69638119D1 (de) 1995-11-22 1996-11-04 Verfahren zur Erhöhung der mageren Fleischmasse mit Fettleibigkeitsprotein (OB) Zusammensetzungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69638119T Expired - Lifetime DE69638119D1 (de) 1995-11-22 1996-11-04 Verfahren zur Erhöhung der mageren Fleischmasse mit Fettleibigkeitsprotein (OB) Zusammensetzungen

Country Status (15)

Country Link
EP (3) EP1285664B1 (de)
JP (2) JP4173914B2 (de)
AT (2) ATE455554T1 (de)
AU (3) AU7607496A (de)
CA (2) CA2358862A1 (de)
DE (2) DE69631544T2 (de)
DK (1) DK0866720T3 (de)
ES (2) ES2217327T3 (de)
IL (2) IL124442A0 (de)
MX (1) MX9803992A (de)
NZ (3) NZ511617A (de)
PT (1) PT866720E (de)
SI (1) SI0866720T1 (de)
WO (1) WO1997018833A1 (de)
ZA (1) ZA969605B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
ATE455554T1 (de) * 1995-11-22 2010-02-15 Amgen Inc Verfahren zur erhöhung der mageren fleischmasse mit fettleibigkeitsprotein (ob) zusammensetzungen
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
EP0877627A1 (de) * 1996-01-25 1998-11-18 Eli Lilly And Company Analoge verbindungen des obesitätsproteins und ihre zubereitungen
AU2810497A (en) * 1996-04-19 1997-11-12 University Of Washington Methods for inducing bone formation
EP1835030A1 (de) * 1996-12-20 2007-09-19 Amgen, Inc. ob-Fusionsprotein enthaltende Zusammensetzungen und Verfahren
AU5802898A (en) * 1996-12-20 1998-07-17 Eli Lilly And Company Anti-obesity proteins
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
EP0950417A3 (de) 1998-02-23 2000-02-23 Pfizer Products Inc. Behandlung von Skeletterkrankungen
WO1999053939A1 (en) * 1998-04-20 1999-10-28 Mayo Foundation For Medical Education And Research Treatment of osteoporosis with leptin
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
WO2000024418A1 (en) * 1998-10-27 2000-05-04 Eli Lilly And Company Prevention of muscle mass loss with leptin receptor ligands
DE60027409T2 (de) * 1999-02-12 2007-04-12 Amgen Inc., Thousand Oaks Glykosylierte leptinzusammensetzungen und zugehörige verfahren
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
DE60237100D1 (de) 2001-10-22 2010-09-02 Amgen Inc Verwendung von leptin zur behandlung von lipoatropr prädisposition gegenüber der behandlung
CA2478183C (en) 2002-03-12 2010-02-16 Merck & Co. Inc. Substituted amides
JP2008505119A (ja) * 2004-06-30 2008-02-21 ネクター セラピューティクス アラバマ，コーポレイション 高分子−第ｉｘ因子部分の抱合体
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
US20090156474A1 (en) 2004-11-01 2009-06-18 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
WO2008048691A2 (en) * 2006-10-18 2008-04-24 Amylin Pharmaceuticals, Inc. Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
EA032917B1 (ru) 2010-09-28 2019-08-30 Амилин Фармасьютикалс, Ллк Сконструированные полипептиды, характеризующиеся увеличенной продолжительностью действия
RU2768868C2 (ru) 2012-09-27 2022-03-25 Дзе Чилдрен'З Медикал Сентер Корпорейшн Соединения, предназначенные для лечения ожирения, и способы их применения
DK3074033T3 (en) 2013-11-26 2019-02-11 Childrens Medical Ct Corp RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
SI3509624T1 (sl) 2016-09-12 2023-12-29 Amryt Pharmaceuticals, Inc., Postopki detektiranja nevtralizirajočih protiteles proti leptinu

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1228925B (it) * 1987-08-07 1991-07-10 Eniricerche Spa Procedimento per la preparazione dell'ormone della crescita umano
DK173142B1 (da) * 1988-08-24 2000-02-07 Natinco Nv Fremgangsmåde til forbedring af kødkvaliteten og foderomsætningseffektiviteten for grise
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US5769954A (en) * 1993-08-13 1998-06-23 Putzmeister Aktiengesellschaft Process and device for treating the surface of large objects
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
ATE455554T1 (de) * 1995-11-22 2010-02-15 Amgen Inc Verfahren zur erhöhung der mageren fleischmasse mit fettleibigkeitsprotein (ob) zusammensetzungen
BR9612359A (pt) * 1995-12-27 1999-07-13 Genentech Inc Derivado covalente de uma proteína ob composição polipeptídeo quimérico sequência de ácido nucleico vetor de express o replicável célula hospedeira e métodos associados aos mesmos
EP1835030A1 (de) * 1996-12-20 2007-09-19 Amgen, Inc. ob-Fusionsprotein enthaltende Zusammensetzungen und Verfahren
JP4086908B2 (ja) * 1997-04-17 2008-05-14 アムジエン・インコーポレーテツド 安定かつ活性なヒトＯＢタンパク質と抗体Ｆｃ鎖とのコンジュゲートを含む組成物および方法

Also Published As

Publication number Publication date
AU7607496A (en) 1997-06-11
AU763755B2 (en) 2003-07-31
ATE259243T1 (de) 2004-02-15
AU4265200A (en) 2000-09-21
AU4265300A (en) 2000-09-07
EP1285664A3 (de) 2003-07-30
DK0866720T3 (da) 2004-06-14
NZ527007A (en) 2005-01-28
JP2002206000A (ja) 2002-07-23
CA2236163A1 (en) 1997-05-29
MX9803992A (es) 1998-09-30
JP4173914B2 (ja) 2008-10-29
NZ511617A (en) 2003-08-29
WO1997018833A1 (en) 1997-05-29
ATE455554T1 (de) 2010-02-15
IL124442A0 (en) 1998-12-06
EP0866720A1 (de) 1998-09-30
AU763769B2 (en) 2003-07-31
NZ512083A (en) 2003-02-28
DE69638119D1 (de) 2010-03-11
EP0956862A1 (de) 1999-11-17
DE69631544T2 (de) 2004-12-23
ES2217327T3 (es) 2004-11-01
EP1285664A2 (de) 2003-02-26
ES2339846T3 (es) 2010-05-26
PT866720E (pt) 2004-06-30
EP1285664B1 (de) 2010-01-20
JP2000500492A (ja) 2000-01-18
SI0866720T1 (en) 2004-10-31
EP0866720B1 (de) 2004-02-11
IL127926A0 (en) 1999-11-30
ZA969605B (en) 1997-06-02
JP4227325B2 (ja) 2009-02-18
CA2358862A1 (en) 1997-05-29
IL127926A (en) 2006-08-20

Similar Documents

Publication Publication Date Title
ATE259243T1 (de) Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse
EA200300845A1 (ru) Модифицированные антитела и способы применения
DK0733067T3 (da) N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
RO117177B1 (ro) Proteine recombinante, anti-obezitate, murine şi umane, secvenţă adn, care le codifică, procedeu de producere a proteinei şi conjugat cu acestea
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
BR9915679A (pt) Composições e métodos para aumentar a mineralização óssea
ATE458815T1 (de) Homologe des nogo rezeptors
DE69632546D1 (de) Ob proteinderivate mit verlängerter halbwertzeit
BR9508467A (pt) Composição de matéria peptídeo de ligação de receptor de somatostatina composição farmacéutica e processo para realizar uma cirurgia guiada por radiosótopos ou um procedimento de radiodiagnóstico ou radioterapéutico e para aliviar uma doença relacionada com somatostetina em um animal
HUP9901688A3 (en) Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
DE69535274D1 (de) Verwendung eines menschlichen interleukin-11 rezeptors
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
DE69010294T2 (de) Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs.
DE69735039D1 (de) Acetylhydrolase des Plättchen aktivierenden Faktors, und entsprechendes Gen
ATE165594T1 (de) Triarylethylenderivate zur therapeutischen verwendung
AU7079300A (en) Compositions and methods for the treatment of immune related diseases
MD899G2 (ro) Procedeu de activizare a osteogenezei reparatorii

Legal Events

Date Code Title Description
8364 No opposition during term of opposition